QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
Log in
NASDAQ:AMED

Amedisys Stock Forecast, Price & News

$244.43
+3.18 (+1.32 %)
(As of 03/8/2021 12:00 AM ET)
Add
Compare
Today's Range
$237.81
Now: $244.43
$251.10
50-Day Range
$236.62
MA: $287.27
$314.16
52-Week Range
$132.95
Now: $244.43
$325.12
Volume435,840 shs
Average Volume183,080 shs
Market Capitalization$8.03 billion
P/E Ratio48.98
Dividend YieldN/A
Beta0.77
Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including heart disease, pulmonary disease, Alzheimer's, or cancer. The Personal Care segment provides assistance for patients with the activities of daily living. As of February 18, 2020, the company owned and operated 479 care centers in 38 states and the District of Columbia. Amedisys, Inc. was founded in 1982 and is headquartered in Baton Rouge, Louisiana.
Amedisys logo

Headlines

Amedisys: Q4 Earnings Insights - Benzinga
February 25, 2021 |  benzinga.com
P/E Ratio Insights for Amedisys - Yahoo Finance
February 25, 2021 |  finance.yahoo.com
Amedisys Becomes Oversold (AMED)
February 25, 2021 |  nasdaq.com
P/E Ratio Insights for Amedisys
February 25, 2021 |  finance.yahoo.com
Amedisys Q4 adjusted earnings Beat Estimates
February 25, 2021 |  nasdaq.com
Amedisys: Q4 Earnings Insights
February 25, 2021 |  finance.yahoo.com
Amedisys announces executive promotions - Seeking Alpha
February 24, 2021 |  seekingalpha.com
See More Headlines

Industry, Sector and Symbol

Industry Home health care services
Sub-IndustryHealth Care Services
SectorMedical
Current SymbolNASDAQ:AMED
CUSIP02343610
Phone225-292-2031
Employees21,000
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.96 billion
Cash Flow$5.17 per share
Book Value$19.89 per share

Profitability

Net Income$126.83 million

Miscellaneous

Market Cap$8.03 billion
Next Earnings Date5/5/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.37 out of 5 stars

Medical Sector

656th out of 1,971 stocks

Home Health Care Services Industry

5th out of 9 stocks

Analyst Opinion: 2.4Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$244.43
+3.18 (+1.32 %)
(As of 03/8/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AMED News and Ratings via Email

Sign-up to receive the latest news and ratings for AMED and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Amedisys (NASDAQ:AMED) Frequently Asked Questions

Is Amedisys a buy right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last twelve months. There are currently 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Amedisys stock.
View analyst ratings for Amedisys
or view top-rated stocks.

What stocks does MarketBeat like better than Amedisys?

Wall Street analysts have given Amedisys a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Amedisys wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Amedisys' next earnings date?

Amedisys is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Amedisys
.

How were Amedisys' earnings last quarter?

Amedisys, Inc. (NASDAQ:AMED) released its earnings results on Tuesday, February, 23rd. The health services provider reported $1.49 EPS for the quarter, topping analysts' consensus estimates of $1.47 by $0.02. Amedisys had a trailing twelve-month return on equity of 26.41% and a net margin of 8.22%. During the same period in the previous year, the company posted $0.94 earnings per share.
View Amedisys' earnings history
.

How has Amedisys' stock price been impacted by COVID-19 (Coronavirus)?

Amedisys' stock was trading at $170.47 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AMED shares have increased by 43.4% and is now trading at $244.43.
View which stocks have been most impacted by COVID-19
.

What guidance has Amedisys issued on next quarter's earnings?

Amedisys updated its FY21 earnings guidance on Wednesday, February, 24th. The company provided EPS guidance of $6.25-6.47 for the period, compared to the Thomson Reuters consensus estimate of $6.33. The company issued revenue guidance of $2.275-2.315 billion, compared to the consensus revenue estimate of $2.31 billion.

What price target have analysts set for AMED?

12 brokers have issued 1 year price objectives for Amedisys' stock. Their forecasts range from $190.00 to $340.00. On average, they anticipate Amedisys' stock price to reach $274.46 in the next year. This suggests a possible upside of 12.3% from the stock's current price.
View analysts' price targets for Amedisys
or view top-rated stocks among Wall Street analysts.

Who are Amedisys' key executives?

Amedisys' management team includes the following people:
  • Mr. Paul Berthold Kusserow, Chairman, Pres & CEO (Age 60, Pay $1.33M)
  • Mr. Scott G. Ginn, Chief Financial Officer (Age 52, Pay $1.22M)
  • Mr. Christopher T. Gerard, Chief Operating Officer (Age 54, Pay $1.34M)
  • Mr. David L. Kemmerly, Chief Legal & Gov. Affairs Officer (Age 58, Pay $851.77k)
  • Ms. Sharon Brunecz, Chief HR Officer (Age 54, Pay $844.58k)
  • Mr. Pete Hartley, CTO & Sr. VP of Bus. Operations Systems
  • Mr. Michael P. North, Chief Information Officer (Age 56)
  • Mr. Denise Bohnert, Chief Compliance Officer (Age 43)
  • Kendra Kimmons, VP of Marketing & Communications
  • Mr. John Nugent, Chief Acquisitions Officer

What is Paul B. Kusserow's approval rating as Amedisys' CEO?

297 employees have rated Amedisys CEO Paul B. Kusserow on Glassdoor.com. Paul B. Kusserow has an approval rating of 79% among Amedisys' employees.

Who are some of Amedisys' key competitors?

What other stocks do shareholders of Amedisys own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Adobe (ADBE), Intel (INTC), QUALCOMM (QCOM), Broadcom (AVGO), Cisco Systems (CSCO) and The Home Depot (HD).

What is Amedisys' stock symbol?

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

Who are Amedisys' major shareholders?

Amedisys' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (12.13%), Price T Rowe Associates Inc. MD (4.76%), JPMorgan Chase & Co. (3.47%), William Blair Investment Management LLC (2.29%), Riverbridge Partners LLC (2.25%) and Wells Fargo & Company MN (1.96%). Company insiders that own Amedisys stock include Bruce D Perkins, Christopher Gerard, David B Pearce, David L Kemmerly, Denise M Bohnert, Donald A Washburn, Jake L Netterville, Jeffrey A Rideout, Julie D Klapstein, Michael Paul North, Scott G Ginn, Sharon Brunecz, Teresa L Kline and Vickie L Capps.
View institutional ownership trends for Amedisys
.

Which major investors are selling Amedisys stock?

AMED stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Dimensional Fund Advisors LP, Dimensional Fund Advisors LP, Ninety One UK Ltd, Squarepoint Ops LLC, Renaissance Technologies LLC, Pembroke Management LTD, and Victory Capital Management Inc.. Company insiders that have sold Amedisys company stock in the last year include Christopher Gerard, David L Kemmerly, Denise M Bohnert, Julie D Klapstein, Michael Paul North, Scott G Ginn, and Sharon Brunecz.
View insider buying and selling activity for Amedisys
or view top insider-selling stocks.

Which major investors are buying Amedisys stock?

AMED stock was purchased by a variety of institutional investors in the last quarter, including Norges Bank, Thornburg Investment Management Inc., BlackRock Inc., JPMorgan Chase & Co., Alliancebernstein L.P., Price T Rowe Associates Inc. MD, Riverbridge Partners LLC, and AGF Investments Inc.. Company insiders that have bought Amedisys stock in the last two years include Bruce D Perkins, Teresa L Kline, and Vickie L Capps.
View insider buying and selling activity for Amedisys
or or view top insider-buying stocks.

How do I buy shares of Amedisys?

Shares of AMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amedisys' stock price today?

One share of AMED stock can currently be purchased for approximately $244.43.

How much money does Amedisys make?

Amedisys has a market capitalization of $8.03 billion and generates $1.96 billion in revenue each year. The health services provider earns $126.83 million in net income (profit) each year or $4.40 on an earnings per share basis.

How many employees does Amedisys have?

Amedisys employs 21,000 workers across the globe.

What is Amedisys' official website?

The official website for Amedisys is www.amedisys.com.

Where are Amedisys' headquarters?

Amedisys is headquartered at 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816.

How can I contact Amedisys?

Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider can be reached via phone at 225-292-2031 or via email at [email protected]


This page was last updated on 3/8/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.